Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.46 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | F9 | P00740 | 3/20 | 0.44 |
| ▸ | F11 | P03951 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896427 | 0.86 | TTBK1 (0.55) | GALR3EGFRRAB9ANPC1ADORA3 | |
| SCHEMBL17815581 | 0.83 | EGFR (0.49) | GALR3EGFRRAB9AMAPTLMNA | |
| SCHEMBL1898192 | 0.83 | EGFR (0.53) | EGFRRAB9AMAPK1NPC1POLB | |
| SCHEMBL16363381 | 0.83 | EGFR (0.54) | GALR3EGFRRAB9AMAPK1NPC1 | |
| SCHEMBL17815590 | 0.80 | BRAF (0.53) | EGFRRAB9ANPC1POLBMAPT | |
| SCHEMBL769494 | 0.80 | EGFR (0.54) | EGFRTTBK1TRPV1 | |
| SCHEMBL9726894 | 0.80 | ABCG2 (0.54) | GALR3EGFRRAB9ATTBK1TTBK2 | |
| Hydrochloric Acid SCHEMBL4203714 | 0.78 | EGFR (0.53) | EGFRTTBK1TRPV1 | |
| SCHEMBL17802606 | 0.78 | MKNK1 (0.54) | EGFRMAPTTTBK1TTBK2F9 | |
| SCHEMBL17802598 | 0.78 | CA1 (0.67) | EGFRMAPTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | GALR3 2347/4885EGFR 1817/4885RAB9A 2141/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | GALR3 2347/4885EGFR 1817/4885RAB9A 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.